Crinetics Pharmaceuticals, Inc. - 8-K Filing
Crinetics Pharmaceuticals reported $10.7 million in revenue for Q1 2026, up from $0.4 million in the same period in 2025, driven by $10.3 million in net product revenue from PALSONIFY. The company reported a net loss of $127.8 million for the quarter, compared to $96.8 million in Q1 2025. R&D expenses were $100.1 million, and SG&A expenses were $50.8 million. The company has $1.3 billion in cash and equivalents as of March 31, 2026, including $380 million from a January 2026 equity offering. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CRNX